CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter's five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidence and prevalence of target conditions
3.5.1.2.Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.5.1.3.Surge in adoption of SPECT and PET scans
3.5.1.4.Developments in imaging technologies using radiopharmaceuticals
3.5.2.Restraint
3.5.2.1.Supply volatility, logistical challenges and stringent regulatory policies
3.5.2.2.Short half life of radiopharmaceuticals
3.5.2.3.Competition from conventional alternative diagnostic procedures
3.5.3.Opportunities
3.5.3.1.Use of radiopharmaceuticals in neurological applications
3.5.4.Impact analysis
3.6.COVID-19 Impact Analysis on Asia-Pacific nuclear medicines Market

CHAPTER 4:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Diagnostics
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.3.Therapeutics
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.4.Biochemistry Research
4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast

CHAPTER 5:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY
5.1.Overview
5.1.1.Market size and forecast
5.2.SPECT
5.2.1.Market size and forecast
5.3.PET
5.3.1.Market size and forecast
5.4.Beta emitters'
5.4.1.Market size and forecast
5.5.Alpha emitters
5.5.1.Market size and forecast
5.6.Brachytherapy
5.6.1.Market size and forecast
5.7.Others
5.7.1.Market size and forecast

CHAPTER 6:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION
6.1.Overview
6.1.1.Key market trends and opportunities
6.1.2.Market size and forecast
6.2.Oncology
6.2.1.Market size and forecast
6.3.Cardiology
6.3.1.Market size and forecast
6.4.Thyroid
6.4.1.Market size and forecast
6.5.Neurology
6.5.1.Market size and forecast
6.6.Others
6.6.1.Market size and forecast

CHAPTER 7:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Hospitals and Diagnostic Centers
7.2.1.Market size and forecast
7.3.Research Institutes
7.3.1.Market size and forecast

CHAPTER 8:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY REGION
8.1.Overview
8.2.Asia-Pacific
8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by country
8.2.2.1.Japan
8.2.2.1.1.Asia-Pacific nuclear medicine market, for Japan, by type
8.2.2.1.2.Asia-Pacific nuclear medicine market, for Japan, by modality
8.2.2.1.3.Asia-Pacific nuclear medicine market, for Japan, by application
8.2.2.1.4.Asia-Pacific nuclear medicine market, for Japan, by end user
8.2.2.2.China
8.2.2.2.1.Asia-Pacific nuclear medicine market, for China, by type
8.2.2.2.2.Asia-Pacific nuclear medicine market, for China, by modality
8.2.2.2.3.Asia-Pacific nuclear medicine market, for China, by application
8.2.2.2.4.Asia-Pacific nuclear medicine market, for China, by end user
8.2.2.3.India
8.2.2.3.1.Asia-Pacific nuclear medicine market, for India, by type
8.2.2.3.2.Asia-Pacific nuclear medicine market, for India, by modality
8.2.2.3.3.Asia-Pacific nuclear medicine market, for India, by application
8.2.2.3.4.Asia-Pacific nuclear medicine market, for India, by end user
8.2.2.4.South Korea
8.2.2.4.1.Asia-Pacific nuclear medicine market, for South Korea, by type
8.2.2.4.2.Asia-Pacific nuclear medicine market, for South Korea, by modality
8.2.2.4.3.Asia-Pacific nuclear medicine market, for South Korea, by application
8.2.2.4.4.Asia-Pacific nuclear medicine market, for South Korea, by end user
8.2.2.5.Australia
8.2.2.5.1.Asia-Pacific nuclear medicine market, for Australia, by type
8.2.2.5.2.Asia-Pacific nuclear medicine market, for Australia, by modality
8.2.2.5.3.Asia-Pacific nuclear medicine market, for Australia, by application
8.2.2.5.4.Asia-Pacific nuclear medicine market, for Australia, by end user
8.2.2.6.Rest of Asia-Pacific
8.2.2.6.1.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by type
8.2.2.6.2.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by modality
8.2.2.6.3.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by application
8.2.2.6.4.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by end user
8.2.3.Asia-Pacific market size and forecast, by type
8.2.4.Asia-Pacific market size and forecast, by modality
8.2.5.Asia-Pacific market size and forecast, by application
8.2.6.Asia-Pacific market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES
9.1.Bracco S.P.A. (Bracco Imaging S.P.A.)
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Key strategic moves and developments
9.2.Bwx Technologies, Inc. (Nordion, Inc.)
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.Cardinal Health, Inc.
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.4.Danaher Corporation (GE Healthcare)
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments
9.5.FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.Ion Beam Applications (Ion Beam Applications, SA)
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments
9.7.Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance
9.8.Novartis AG (Advanced Accelerator Applications S.A.)
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.9.Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.10.Siemens Healthcare GmbH
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance

List of Tables

TABLE 01.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE, 2020-2028($MILLION)
TABLE 02.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY, 2020-2028($MILLION)
TABLE 03.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020-2028($MILLION)
TABLE 04.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER, 2020-2028($MILLION)
TABLE 05.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 06.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY MODALITY, 2020-2028
TABLE 07.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY APPLICATION, 2020-2028
TABLE 08.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR JAPAN, BY END USER, 2020-2028
TABLE 09.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY TYPE, 2020-2028
TABLE 10.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY MODALITY, 2020-2028
TABLE 11.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, CHINA, BY APPLICATION, 2020-2028
TABLE 12.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR CHINA, BY END USER, 2020-2028
TABLE 13.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY TYPE, 2020-2028
TABLE 14.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY MODALITY, 2020-2028
TABLE 15.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, INDIA, BY APPLICATION, 2020-2028
TABLE 16.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR INDIA, BY END USER, 2020-2028
TABLE 17.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY TYPE, 2020-2028
TABLE 18.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY MODALITY, 2020-2028
TABLE 19.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, SOUTH KOREA, BY APPLICATION, 2020-2028
TABLE 20.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR SOUTH KOREA, BY END USER, 2020-2028
TABLE 21.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY TYPE, 2020-2028
TABLE 22.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY MODALITY, 2020-2028
TABLE 23.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, AUSTRALIA, BY APPLICATION, 2020-2028
TABLE 24.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR AUSTRALIA, BY END USER, 2020-2028
TABLE 25.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY TYPE, 2020-2028
TABLE 26.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY MODALITY, 2020-2028
TABLE 27.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR, REST OF ASIA-PACIFIC, BY APPLICATION, 2020-2028
TABLE 28.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, FOR REST OF ASIA-PACIFIC, BY END USER, 2020-2028
TABLE 29.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE, 2020-2028
TABLE 30.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY, 2020-2028
TABLE 31.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2020-2028
TABLE 32.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER, 2020-2028
TABLE 33.BRACCO S.P.A.: COMPANY SNAPSHOT
TABLE 34.BRACCO S.P.A.: OPERATING SEGMENTS
TABLE 35.BRACCO S.P.A.: PRODUCT PORTFOLIO
TABLE 36.BRACCO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 37.BWXT: COMPANY SNAPSHOT
TABLE 38.BWXT: OPERATING SEGMENT
TABLE 39.BWXT: PRODUCT PORTFOLIO
TABLE 40.BWXT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 41.CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 42.CARDINAL HEALTH: OPERATING SEGMENT
TABLE 43.CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 44.DANAHER: COMPANY SNAPSHOT
TABLE 45.DANAHER: OPERATING SEGMENT
TABLE 46.DANAHER: PRODUCT PORTFOLIO
TABLE 47.GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 48.FUJIFILM: COMPANY SNAPSHOT
TABLE 49.FUJIFILM: OPERATING SEGMENT
TABLE 50.FUJIFILM: PRODUCT PORTFOLIO
TABLE 51.IBA: COMPANY SNAPSHOT
TABLE 52.IBA: OPERATING SEGMENT
TABLE 53.IBA: PRODUCT PORTFOLIO
TABLE 54.IBA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 55.LANTHEUS: COMPANY SNAPSHOT
TABLE 56.LANTHEUS: OPERATING SEGMENTS
TABLE 57.LANTHEUS: PRODUCT PORTFOLIO
TABLE 58.NOVARTIS: COMPANY SNAPSHOT
TABLE 59.NOVARTIS: OPERATING SEGMENTS
TABLE 60.NOVARTIS: PRODUCT PORTFOLIO
TABLE 61.OTSUKA: COMPANY SNAPSHOT
TABLE 62.OTSUKA: OPERATING SEGMENT
TABLE 63.OTSUKA: PRODUCT PORTFOLIO
TABLE 64.SIEMENS: COMPANY SNAPSHOT
TABLE 65.SIEMENS: OPERATING SEGMENTS
TABLE 66.SIEMENS: PRODUCT PORTFOLIO

List of Figures

FIGURE 01.ASIA-PACIFIC NUCLEAR MEDICINES MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017-2021
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.MODERATE THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, DIAGNOSTICS, BY COUNTRY, 2020-2028 ($MILLION)
FIGURE 09.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, THERAPEUTICS, BY COUNTRY, 2020-2028 ($MILLION)
FIGURE 10.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BIOCHEMISTRY RESEARCH, BY COUNTRY, 2020-2028 ($MILLION)
FIGURE 11.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY SPECT, 2020-2028 ($MILLION)
FIGURE 12.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY PET, 2020-2028 ($MILLION)
FIGURE 13.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY BETA EMITTERS, 2020-2028 ($MILLION)
FIGURE 14.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY ALPHA EMITTERS, 2020-2028 ($MILLION)
FIGURE 15.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY BRACHYTHERAPY, 2020-2028 ($MILLION)
FIGURE 16.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY OTHERS, 2020-2028 ($MILLION)
FIGURE 17.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY ONCOLOGY, 2020-2028 ($MILLION)
FIGURE 18.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY CARDIOLOGY, 2020-2028 ($MILLION)
FIGURE 19.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY THYROID, 2020-2028 ($MILLION)
FIGURE 20.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY NEUROLOGY, 2020-2028 ($MILLION)
FIGURE 21.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY OTHERS, 2020-2028 ($MILLION)
FIGURE 22.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY HOSPITALS AND DIAGNOSTIC CENTERS, 2020-2028 ($MILLION)
FIGURE 23.ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY RESEARCH INSTITUTES, 2020-2028 ($MILLION)
FIGURE 24.BWXT: NET SALES, 2018-2020($MILLION)
FIGURE 25.BWXT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.BWXT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27.CARDINAL HEALTH: NET SALES, 2018-2020($MILLION)
FIGURE 28.CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30.DANAHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 31.DANAHER: REVENUE SHARE BY SEGMENT, 2020
FIGURE 32.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33.FUJIFILM: NET SALES, 2017-2019 ($MILLION)
FIGURE 34.FUJIFILM: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 35.IBA: NET SALES, 2018-2020($MILLION)
FIGURE 36.IBA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.LANTHEUS: NET SALES, 2018-2020($MILLION)
FIGURE 38.LANTHEUS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 39.NOVARTIS: NET SALES, 2018-2020($MILLION)
FIGURE 40.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 41.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.OTSUKA: NET SALES, 2018-2020($MILLION)
FIGURE 43.OTSUKA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.SIEMENS: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)

Companies Mentioned
The key players operating in the market are Bracco S.P.A. (Bracco Imaging S.P.A.), Bwx Technologies, Inc. (Nordion, Inc.), Cardinal Health, Inc., Danaher Corporation (GE Healthcare), FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation), Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH), and Siemens Healthcare GmbH.